ESSA Pharma Inc. (V:EPI*CA)
Business Focus: Biotechnology & Medical Research (NEC)
Feb 25, 2021 05:33 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting").
Feb 25, 2021 05:33 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting").
Jan 13, 2021 06:00 am ET
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 13, 2021 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Janssen Research & Development, LLC (Janssen) to evaluate ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with met
Jan 13, 2021 06:00 am ET
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 13, 2021 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Janssen Research & Development, LLC (Janssen) to evaluate ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients w
Dec 15, 2020 04:01 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
VANCOUVER and HOUSTON, Dec. 15, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Dec 15, 2020 04:01 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Nov 25, 2020 06:00 am ET
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference.
Nov 25, 2020 06:00 am ET
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference.
Oct 26, 2020 05:01 pm ET
ESSA Pharma Inc. Announces Delisting from the TSX-V
HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today its intention to voluntarily delist all of its issued and outstanding common shares (the "Shares"), currently listed under symbol "EPI", from the TSX Venture Exchange (the "TSX-V"), which is currently anticipated to occur on or about October 30, 2020.
Oct 26, 2020 05:01 pm ET
ESSA Pharma Inc. Announces Delisting from the TSX-V
HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today its intention to voluntarily delist all of its issued and outstanding common shares (the "Shares"), currently listed under symbol "EPI", from the TSX Venture Exchange (the "TSX-V"), which is currently anticipated to occur on or about October 30, 2020.
Oct 24, 2020 07:18 pm ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics ("ENA").
Oct 24, 2020 07:18 pm ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics ("ENA").
Oct 19, 2020 07:00 am ET
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON, Texas and VANCOUVER, BC, Oct. 19, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that several abstracts on ESSA's clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386.
Oct 19, 2020 07:00 am ET
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON, Texas and VANCOUVER, BC, Oct. 19, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that several abstracts on ESSA's clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386.
Sep 21, 2020 07:00 am ET
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd at 11:40am Eastern
Sep 17, 2020 05:05 pm ET
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of data of ESSA's clinical candidate, EPI-7386, at the ESMO Virtual Congress 2020.
Sep 14, 2020 07:00 am ET
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX) (TSXV: EPI) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer today announced that the U.S. Food and Drug Administration ("FDA") granted Fast Track Designation to EPI-7386, its oral and highly-selective N-terminal domain inhibitor of the androgen receptor, for the treatment of adult male patients with metastatic castration-resistant prostate cancer ("mCRPC") resistant to standard-of-care treatment.
Sep 10, 2020 07:00 am ET
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
HOUSTON and VANCOUVER, BC, Sept. 10, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 and at the Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday September 17, 2020.
Aug 06, 2020 08:00 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 06, 2020 08:00 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jul 31, 2020 10:16 am ET
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common sha
Jul 31, 2020 10:16 am ET
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
HOUSTON and VANCOUVER, BC, July 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 com
Jul 29, 2020 09:05 am ET
IIROC Trading Resumption - EPI
VANCOUVER, BC, July 29, 2020 /CNW/ - Trading resumes in:
Jul 28, 2020 09:18 pm ET
ESSA Pharma Announces Pricing of Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 7,100,000 common shares at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 1,065,000
Jul 28, 2020 09:18 pm ET
ESSA Pharma Announces Pricing of Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 7,100,000 common shares at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 1,
Jul 28, 2020 04:01 pm ET
ESSA Pharma Announces Proposed Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of its common shares (the "Offering"). ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. In connection with the Offering,
Jul 28, 2020 04:01 pm ET
ESSA Pharma Announces Proposed Public Offering of Common Shares
VANCOUVER, BC and HOUSTON, July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of its common shares (the "Offering"). ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. In connection with the Off
Jul 28, 2020 04:01 pm ET
IIROC Trading Halt - EPI
VANCOUVER, BC, July 28, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 15, 2020 07:00 am ET
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
HOUSTON and VANCOUVER, BC, July 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer ("mCRPC") patients who failed standard of care treatments, including second generation anti-androgens. EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor (AR) which h
Jul 15, 2020 07:00 am ET
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
HOUSTON and VANCOUVER, BC, July 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer ("mCRPC") patients who failed standard of care treatments, including second generation anti-androgens. EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor (AR)
Jun 22, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
HOUSTON and VANCOUVER, BC, June 22, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 American Association for Cancer Research ("AACR") Virtual Annual Meeting II.
Jun 22, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
HOUSTON and VANCOUVER, BC, June 22, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 American Association for Cancer Research ("AACR") Virtual Annual Meeting II.
May 27, 2020 07:00 am ET
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
HOUSTON and VANCOUVER, May 27, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference on Thursday June 4, 2020 at 3:30pm Eastern.
May 27, 2020 07:00 am ET
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
HOUSTON and VANCOUVER, May 27, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference on Thursday June 4, 2020 at 3:30pm Eastern.
May 15, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
HOUSTON and VANCOUVER, May 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 Virtual American Urological Association ("AUA") Annual Meeting.
May 15, 2020 07:30 am ET
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
HOUSTON and VANCOUVER, May 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 Virtual American Urological Association ("AUA") Annual Meeting.
May 07, 2020 05:05 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
VANCOUVER and HOUSTON, May 7, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 07, 2020 05:05 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
VANCOUVER and HOUSTON, May 7, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2020. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Apr 30, 2020 05:45 pm ET
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
VANCOUVER and HOUSTON, April 30, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration ("FDA") has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). ESSA previously announced on March 30th, 2020 that it had filed an Investigational New Drug ("IND") application for EPI-7386 with the
Apr 30, 2020 05:45 pm ET
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
VANCOUVER and HOUSTON, April 30, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration ("FDA") has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). ESSA previously announced on March 30th, 2020 that it had filed an Investigational New Drug ("IND") application for EPI-7386 wi
Apr 13, 2020 06:08 pm ET
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
VANCOUVER and HOUSTON, April 13, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of April 13, 2020. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$35.0 million in aggregate sales proceeds in "at-the-market" transactions. No offers or sales of common
Apr 13, 2020 06:08 pm ET
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
VANCOUVER and HOUSTON, April 13, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of April 13, 2020. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$35.0 million in aggregate sales proceeds in "at-the-market" transactions. No offers or sales of
Mar 31, 2020 07:00 am ET
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
VANCOUVER and HOUSTON, March 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Mar 31, 2020 07:00 am ET
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
VANCOUVER and HOUSTON, March 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Feb 27, 2020 06:51 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, Feb. 27, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "Meeting").
Feb 13, 2020 04:48 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
VANCOUVER and HOUSTON, TX, Feb. 13, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Feb 10, 2020 05:15 pm ET
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON and VANCOUVER, Feb. 10, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that several abstracts on ESSA's lead clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386 including new preclinical data regarding safety studies, gene expression and combination data with antiandrogens.
Dec 19, 2019 04:15 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
VANCOUVER and HOUSTON, Dec. 19, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Nov 11, 2019 09:00 am ET
Encode Ideas, L.P. Announces the Initiation of Research Coverage on ESSA Pharma, Inc.
Dover, Delaware--(Newsfile Corp. - November 11, 2019) - Encode Ideas, L.P. Initiates Research on ESSA Pharma, Inc. (NASDAQ: EPIX). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:
Oct 30, 2019 06:00 am ET
ESSA Pharma Grants Stock Options
HOUSTON and VANCOUVER, Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date. The stock options are exercisable on or before October 30, 2029 a
Oct 30, 2019 06:00 am ET
ESSA Pharma Grants Stock Options
HOUSTON and VANCOUVER, Oct. 30, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date. The stock options are exercisable on or before October 30,
Oct 28, 2019 07:30 am ET
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
HOUSTON and VANCOUVER, Oct. 28, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Oct 28, 2019 07:30 am ET
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
HOUSTON and VANCOUVER, Oct. 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Oct 18, 2019 04:15 pm ET
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.
Oct 18, 2019 04:15 pm ET
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.
Oct 07, 2019 02:04 pm ET
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
VANCOUVER and HOUSTON, Oct. 7, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that, pursuant to the Company's existing stock option plan (the "Existing Option Plan"), it has granted incentive stock options ("Options") to certain directors, officers, employees and consultants of the Company to purchase up to an aggregate of 1,441,530 common shares in the capital of the Company (the "Common Shares"). A total of 1,186,530 of such Options will
Oct 07, 2019 02:04 pm ET
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
VANCOUVER and HOUSTON, Oct. 7, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that, pursuant to the Company's existing stock option plan (the "Existing Option Plan"), it has granted incentive stock options ("Options") to certain directors, officers, employees and consultants of the Company to purchase up to an aggregate of 1,441,530 common shares in the capital of the Company (the "Common Shares"). A total of 1,186,530 of such Optio
Sep 28, 2019 07:29 am ET
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
HOUSTON and VANCOUVER, Sept. 28, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting.
Sep 28, 2019 07:29 am ET
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
HOUSTON and VANCOUVER, Sept. 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting.
Sep 19, 2019 07:30 am ET
ESSA to Present at Ladenburg Thalmann Healthcare Conference
HOUSTON and VANCOUVER, Sept. 19, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Ladenburg Thalmann Helathcare Conference on Tuesday September 24, 2019 at 9:30am EDT at the Sofitel New York City in New York.
Sep 19, 2019 07:30 am ET
ESSA to Present at Ladenburg Thalmann Healthcare Conference
HOUSTON and VANCOUVER, Sept. 19, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Ladenburg Thalmann Helathcare Conference on Tuesday September 24, 2019 at 9:30am EDT at the Sofitel New York City in New York.
Sep 05, 2019 07:00 am ET
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
HOUSTON and VANCOUVER, Sept. 5, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on Monday September 9, 2019 at 5:05pm EDT at the Lotte New York Palace Hotel in New York.
Sep 05, 2019 07:00 am ET
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
HOUSTON and VANCOUVER, Sept. 5, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on Monday September 9, 2019 at 5:05pm EDT at the Lotte New York Palace Hotel in New York.
Aug 27, 2019 09:21 am ET
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
VANCOUVER and HOUSTON, Aug. 27, 2019 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering"). The Offering was led by Soleus Capital and included RA Capital Management as a ne
Aug 27, 2019 09:21 am ET
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
VANCOUVER and HOUSTON, Aug. 27, 2019 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering"). The Offering was led by Soleus Capital and included RA Capital Management
Aug 23, 2019 10:56 am ET
IIROC Trading Resumption - EPI
VANCOUVER, Aug. 23, 2019 /CNW/ - Trading resumes in:
Aug 23, 2019 10:42 am ET
IIROC Trading Halt - EPI
VANCOUVER, Aug. 23, 2019 /CNW/ - The following issues have been halted by IIROC:
Aug 23, 2019 10:37 am ET
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
VANCOUVER and HOUSTON, Aug. 23, 2019 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering"). The Offering is being led by Soleus Capital and includes RA Capital Management as a new investor. Existing investors, including BVF Partners LP, among others, are also co-investing in the Offering.
Aug 23, 2019 10:37 am ET
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
VANCOUVER and HOUSTON, Aug. 23, 2019 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering"). The Offering is being led by Soleus Capital and includes RA Capital Management as a new investor. Existing investors, including BVF Partners LP, among others, are also co-investing in the Offer
Aug 14, 2019 07:30 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
VANCOUVER and HOUSTON, Aug. 14, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 14, 2019 07:30 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
VANCOUVER and HOUSTON, Aug. 14, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jul 31, 2019 04:45 am ET
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
VANCOUVER and HOUSTON, July 31, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme") has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 31, 2019 04:45 am ET
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
VANCOUVER and HOUSTON, July 31, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme") has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 30, 2019 02:15 am ET
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
VANCOUVER and HOUSTON, TX, July 30, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 30, 2019 02:15 am ET
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
VANCOUVER and HOUSTON, TX, July 30, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm").
Jul 15, 2019 07:30 am ET
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
VANCOUVER and HOUSTON, July 15, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer ("CMO"). With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing.
Jul 15, 2019 07:30 am ET
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
VANCOUVER and HOUSTON, July 15, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer ("CMO"). With over 25 years of drug development, regulatory and medical affairs activities, Dr. Cesano will provide leadership in advancing the Company's lead clinical candidate, EPI-7386 into Phase 1 clinical testing.
Jul 08, 2019 03:39 pm ET
ESSA Provides Update on Court Hearing
VANCOUVER and HOUSTON, July 8, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that the hearing at the High Court of Justice in England and Wales (the "Court") in respect of the proposed scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"), took place today in London.
Jul 08, 2019 03:39 pm ET
ESSA Provides Update on Court Hearing
VANCOUVER and HOUSTON, July 8, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that the hearing at the High Court of Justice in England and Wales (the "Court") in respect of the proposed scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"), pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc ("Realm"), took place today in London.
Jun 26, 2019 06:08 pm ET
ESSA Provides an Update to the Acquisition of Realm Therapeutics
HOUSTON and VANCOUVER, June 26, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc ("Realm") by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the "Scheme"). The Court Meeting and General Meeting in relation to the Scheme were each held by Realm on June 24, 2019 in London, United Kingdom and all resol
Jun 25, 2019 10:40 pm ET
ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders
HOUSTON, TX AND VANCOUVER, June 25, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its annual general meeting of shareholders of the Company (the "Shareholders") held on June 25, 2019 in Vancouver, British Columbia, Canada (the "Meeting").
Jun 21, 2019 08:30 pm ET
ESSA Pharma to Hold Annual Shareholders' Meeting and Announces Three Realm-Nominated Directors
HOUSTON, TX and VANCOUVER, June 21, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer reminds investors that ESSA will hold its Annual General Meeting of Shareholders on Tuesday, June 25, 2019 at 2:00 PT, at the offices of Blake, Cassels & Graydon LLP at Suite 2600, 595 Burrard Street, Vancouver British Columbia, Canada.
May 20, 2019 11:35 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Realm Therapeutics plc to ESSA Pharma Inc., LLC is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Realm Therapeutics plc (“Realm” or the “Company”) (NASDAQCM: RLM) stock prior to May 16, 2019. You are hereby notified that Levi &...
May 16, 2019 11:27 am ET
IIROC Trading Resumption - EPI
VANCOUVER, May 16, 2019 /CNW/ - Trading resumes in:
May 16, 2019 11:01 am ET
IIROC Trading Halt - EPI
VANCOUVER, May 16, 2019 /CNW/ - The following issues have been halted by IIROC:
May 16, 2019 06:30 am ET
Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics
Acquisition Expected to be Completed by Mid-Year 2019
May 16, 2019 06:30 am ET
Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics
Acquisition Expected to be Completed by Mid-Year 2019
May 10, 2019 07:30 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019
HOUSTON, TX and VANCOUVER, May 10, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 10, 2019 07:30 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019
HOUSTON, TX and VANCOUVER, May 10, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 04, 2019 04:00 pm ET
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting
HOUSTON, TX and VANCOUVER, May 4, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting.
May 04, 2019 04:00 pm ET
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting
HOUSTON, TX and VANCOUVER, May 4, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting.
Apr 25, 2019 07:30 am ET
ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019
HOUSTON and VANCOUVER, April 25, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1 at 10:30am Eastern Standard Time at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.
Apr 25, 2019 07:30 am ET
ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019
HOUSTON and VANCOUVER, April 25, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1 at 10:30am Eastern Standard Time at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.
Apr 17, 2019 07:30 am ET
ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting
HOUSTON and VANCOUVER, April 17, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced an abstract on ESSA's aniten compounds for metastatic castration-resistant prostate cancer has been selected for a moderated poster presentation at the upcoming 2019 American Urological Association ("AUA") Annual Meeting from May 3-6 in Chicago, Illinois. ESSA's next generation anitens, inhibitors of the N-terminal domain of the androgen receptor ("AR"), represent a novel therapeutic str
Apr 17, 2019 07:30 am ET
ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting
HOUSTON and VANCOUVER, April 17, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced an abstract on ESSA's aniten compounds for metastatic castration-resistant prostate cancer has been selected for a moderated poster presentation at the upcoming 2019 American Urological Association ("AUA") Annual Meeting from May 3-6 in Chicago, Illinois. ESSA's next generation anitens, inhibitors of the N-terminal domain of the androgen receptor ("AR"), represent a novel therapeu
Apr 12, 2019 02:00 am ET
ESSA Pharma Grants Stock Options
HOUSTON, TX and VANCOUVER, April 12, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to directors and officers, employees and consults of the Corporation to purchase up to an aggregate of 238,000 common shares in the capital of the Corporation (the "Common shares"). Such stock options will vest in 48 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date. The stock options are exercisable on or before February 8
Apr 12, 2019 02:00 am ET
ESSA Pharma Grants Stock Options
HOUSTON, TX and VANCOUVER, April 12, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to directors and officers, employees and consults of the Corporation to purchase up to an aggregate of 238,000 common shares in the capital of the Corporation (the "Common shares"). Such stock options will vest in 48 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date. The stock options are exercisable on or before Feb
Mar 28, 2019 05:02 pm ET
ESSA Pharma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
HOUSTON, TX and VANCOUVER, March 28, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced its lead clinical candidate, EPI-7386, for metastatic castration-resistant prostate cancer has been selected for a poster presentation at the upcoming American Association for Cancer Research ("AACR") Annual Meeting 2019 to be held March 29 – April 3 at the Georgia World Congress Center in Atlanta, Georgia. The poster will expand on the preclinical character
Mar 28, 2019 05:02 pm ET
ESSA Pharma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
HOUSTON, TX and VANCOUVER, March 28, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced its lead clinical candidate, EPI-7386, for metastatic castration-resistant prostate cancer has been selected for a poster presentation at the upcoming American Association for Cancer Research ("AACR") Annual Meeting 2019 to be held March 29 – April 3 at the Georgia World Congress Center in Atlanta, Georgia. The poster will expand on the preclinical ch
Mar 28, 2019 05:01 pm ET
ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, March 28, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the nomination of EPI-7386 as the lead clinical candidate for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). EPI-7386 is a novel drug candidate that inhibits the N-terminal domain of the androgen receptor. Through this novel mechanism of action, EPI-7386 displays activity in vitro in numerous prostate cancer models including models where current antiandrogens
Mar 28, 2019 05:01 pm ET
ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, March 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the nomination of EPI-7386 as the lead clinical candidate for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). EPI-7386 is a novel drug candidate that inhibits the N-terminal domain of the androgen receptor. Through this novel mechanism of action, EPI-7386 displays activity in vitro in numerous prostate cancer models including models where current antian
Mar 18, 2019 07:30 am ET
ESSA Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference
HOUSTON, TX and VANCOUVER, March 18, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Oppenheimer 29th Annual Healthcare Conference on Wednesday March 20 at 3:55pm Eastern Daylight Time at the Westin New York Grand Central in New York City.
Mar 18, 2019 07:30 am ET
ESSA Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference
HOUSTON, TX and VANCOUVER, March 18, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Oppenheimer 29th Annual Healthcare Conference on Wednesday March 20 at 3:55pm Eastern Daylight Time at the Westin New York Grand Central in New York City.
Mar 14, 2019 07:30 am ET
ESSA Pharma to Attend the 31st Annual ROTH Conference
HOUSTON and VANCOUVER, March 14, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be attending the 31st Annual ROTH Conference to be held on March 17 -19 at the Ritz Carlton Laguna Niguel in Dana Point, California. Dr. David R. Parkinson, President & Chief Executive Officer and Peter Virsik, Chief Operating Officer will be available for one-on-one meetings throughout the conference.
Mar 14, 2019 07:30 am ET
ESSA Pharma to Attend the 31st Annual ROTH Conference
HOUSTON and VANCOUVER, March 14, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be attending the 31st Annual ROTH Conference to be held on March 17 -19 at the Ritz Carlton Laguna Niguel in Dana Point, California. Dr. David R. Parkinson, President & Chief Executive Officer and Peter Virsik, Chief Operating Officer will be available for one-on-one meetings throughout the conference.
Feb 11, 2019 06:30 am ET
ESSA Pharma Announces Two Abstracts Selected to be Presented at the 2019 Genitourinary Cancers Symposium
HOUSTON and VANCOUVER, Feb. 11, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced two abstracts on ESSA compounds have been selected for a poster presentation at the upcoming 2019 Genitourinary Cancers Symposium to be held February 14 – 16, 2019 at the Moscone Center in San Francisco, CA.
Feb 11, 2019 06:30 am ET
ESSA Pharma Announces Two Abstracts Selected to be Presented at the 2019 Genitourinary Cancers Symposium
HOUSTON and VANCOUVER, Feb. 11, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced two abstracts on ESSA compounds have been selected for a poster presentation at the upcoming 2019 Genitourinary Cancers Symposium to be held February 14 – 16, 2019 at the Moscone Center in San Francisco, CA.
Feb 07, 2019 04:05 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2018
HOUSTON, TX and VANCOUVER, Feb. 7, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Feb 07, 2019 04:05 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2018
HOUSTON, TX and VANCOUVER, Feb. 7, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Dec 13, 2018 04:02 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2018
HOUSTON, TX and VANCOUVER, Dec. 13, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal fourth quarter and year ended September 30, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Dec 13, 2018 04:02 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2018
HOUSTON, TX and VANCOUVER, Dec. 13, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal fourth quarter and year ended September 30, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Oct 22, 2018 07:00 am ET
ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors
HOUSTON and VANCOUVER, Oct. 22, 2018 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, a Boston-based biotech and medical device investment firm, to the Company's Board of Directors. Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.
Oct 22, 2018 07:00 am ET
ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors
HOUSTON and VANCOUVER, Oct. 22, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, a Boston-based biotech and medical device investment firm, to the Company's Board of Directors. Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.
Aug 29, 2018 07:00 am ET
ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018
HOUSTON and VANCOUVER, Aug. 29, 2018 /CNW/ - ESSA Pharma Inc. (TSX-V: EPIX, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright, in New York City on Wednesday, September 5th, at 5:05 PM Eastern Standard Time at the St. Regis Hotel in New York.
Aug 29, 2018 07:00 am ET
ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018
HOUSTON and VANCOUVER, Aug. 29, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPIX, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright, in New York City on Wednesday, September 5th, at 5:05 PM Eastern Standard Time at the St. Regis Hotel in New York.
Aug 14, 2018 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018
HOUSTON and VANCOUVER, Aug. 14, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Aug 14, 2018 07:00 am ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018
HOUSTON and VANCOUVER, Aug. 14, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 14, 2018 07:15 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018
HOUSTON and VANCOUVER, May 14, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 14, 2018 07:15 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018
HOUSTON and VANCOUVER, May 14, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2018. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
May 10, 2018 05:05 pm ET
Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
HOUSTON and VANCOUVER, May 10, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, Nasdaq: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that it received a notice from the Nasdaq Listing Qualifications Staff on May 10, 2018 notifying the Company that it regained compliance with the Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"). Accordingly, ESSA is in compliance with all applicable lis
May 10, 2018 05:05 pm ET
Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
HOUSTON and VANCOUVER, May 10, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, Nasdaq: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that it received a notice from the Nasdaq Listing Qualifications Staff on May 10, 2018 notifying the Company that it regained compliance with the Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"). Accordingly, ESSA is in compliance with all applica
Apr 26, 2018 07:00 am ET
ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018
HOUSTON and VANCOUVER, April 26, 2018 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference 2018 on Wednesday, May 2nd, at 10:00am Eastern Time, at the Sheraton Centre Toronto Hotel in Toronto, Canada.
Apr 26, 2018 07:00 am ET
ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018
HOUSTON and VANCOUVER, April 26, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference 2018 on Wednesday, May 2nd, at 10:00am Eastern Time, at the Sheraton Centre Toronto Hotel in Toronto, Canada.
Apr 25, 2018 07:00 am ET
ESSA Pharma Inc. Announces Completion of Share Consolidation
HOUSTON, TX and VANCOUVER, April 25, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that ESSA has consolidated (the "Consolidation") its issued and outstanding common shares (the "Common Shares") on a basis of one (1) post-Consolidation Common Share for every twenty (20) pre-Consolidation Common Shares effective as of April 25, 2018 (the "Effective Date"). Shareholders authorized the Company to effect the Consolid
Apr 25, 2018 07:00 am ET
ESSA Pharma Inc. Announces Completion of Share Consolidation
HOUSTON, TX and VANCOUVER, April 25, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that ESSA has consolidated (the "Consolidation") its issued and outstanding common shares (the "Common Shares") on a basis of one (1) post-Consolidation Common Share for every twenty (20) pre-Consolidation Common Shares effective as of April 25, 2018 (the "Effective Date"). Shareholders authorized the Company to effect the C
Apr 24, 2018 07:30 am ET
ESSA Pharma Enhances R&D Capabilities with Two New Key Hires
HOUSTON and VANCOUVER, April 24, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the appointments of Han-Jie Zhou, Ph.D., Vice President, Chemistry and Chemistry Manufacturing and Control, and Ronan Le Moigne, Ph.D., Senior Director, Preclinical.
Apr 24, 2018 07:30 am ET
ESSA Pharma Enhances R&D Capabilities with Two New Key Hires
HOUSTON and VANCOUVER, April 24, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the appointments of Han-Jie Zhou, Ph.D., Vice President, Chemistry and Chemistry Manufacturing and Control, and Ronan Le Moigne, Ph.D., Senior Director, Preclinical.
Apr 19, 2018 07:38 pm ET
ESSA Pharma Inc. Announces Share Consolidation
HOUSTON and VANCOUVER, April 19, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that on April 18, 2018 the board of directors of the Company (the "Board") passed a resolution to proceed with the previously announced consolidation (the "Consolidation") of the issued and outstanding common shares of the Company (the "Common Shares") on a basis of one (1) post-Consolidation Common Share for every twenty (20) pre-Conso
Apr 19, 2018 07:38 pm ET
ESSA Pharma Inc. Announces Share Consolidation
HOUSTON and VANCOUVER, April 19, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that on April 18, 2018 the board of directors of the Company (the "Board") passed a resolution to proceed with the previously announced consolidation (the "Consolidation") of the issued and outstanding common shares of the Company (the "Common Shares") on a basis of one (1) post-Consolidation Common Share for every twenty (20) pr
Mar 28, 2018 09:56 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, March 28, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on March 28, 2018 in Vancouver, British Columbia, Canada (the "Meeting").
Mar 28, 2018 09:56 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, March 28, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on March 28, 2018 in Vancouver, British Columbia, Canada (the "Meeting").
Feb 23, 2018 08:02 am ET
ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants
HOUSTON and VANCOUVER, Feb. 23, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that on February 21, 2018 the board of directors of the Company ("Board") passed a resolution adopting a new stock option plan (the "New Option Plan") and a restricted share unit plan (the "RSU Plan").
Feb 23, 2018 08:02 am ET
ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants
HOUSTON and VANCOUVER, Feb. 23, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that on February 21, 2018 the board of directors of the Company ("Board") passed a resolution adopting a new stock option plan (the "New Option Plan") and a restricted share unit plan (the "RSU Plan").
Feb 13, 2018 04:00 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
HOUSTON and VANCOUVER, Feb. 13, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2017. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Feb 13, 2018 04:00 pm ET
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
HOUSTON and VANCOUVER, Feb. 13, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2017. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
Jan 26, 2018 06:00 am ET
ESSA to Present at Noble Capital Markets' NobleCon14
HOUSTON and VANCOUVER, Jan. 26, 2018 /CNW/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, President and Chief Executive Officer, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday January 29th at 1:30pm Eastern Standard Time.
Jan 26, 2018 06:00 am ET
ESSA to Present at Noble Capital Markets' NobleCon14
HOUSTON and VANCOUVER, Jan. 26, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, President and Chief Executive Officer, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday January 29th at 1:30pm Eastern Standard Time.
Jan 25, 2018 10:00 pm ET
ESSA Announces Management Team Change
HOUSTON and VANCOUVER, Jan. 25, 2018 /CNW/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that Frank Perabo, M.D., Ph.D., will depart ESSA as the Company's Chief Medical Officer to pursue other opportunities, effective January 31, 2018. Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA's medical advisory committee.
Jan 25, 2018 10:00 pm ET
ESSA Announces Management Team Change
HOUSTON and VANCOUVER, Jan. 25, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that Frank Perabo, M.D., Ph.D., will depart ESSA as the Company's Chief Medical Officer to pursue other opportunities, effective January 31, 2018. Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA's medical advisory committee.
Jan 16, 2018 08:40 pm ET
ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule
HOUSTON and VANCOUVER, Jan. 16, 2018 /CNW/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that it expects to receive a letter (the "Nasdaq Notice") from the Nasdaq Stock Market ("Nasdaq"), granting the Company an additional 180-day period, or until approximately July 16, 2018, to regain compliance with Nasdaq's minimum US$1.00 bid price per share rule (the "Bid Price Rule") for continued listing on the Nasdaq Capital Market.
Jan 16, 2018 08:40 pm ET
ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule
HOUSTON and VANCOUVER, Jan. 16, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that it expects to receive a letter (the "Nasdaq Notice") from the Nasdaq Stock Market ("Nasdaq"), granting the Company an additional 180-day period, or until approximately July 16, 2018, to regain compliance with Nasdaq's minimum US$1.00 bid price per share rule (the "Bid Price Rule") for continued listing on the Nasdaq Capital Market.
Jan 16, 2018 07:40 am ET
ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million
HOUSTON and VANCOUVER, Jan. 16, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company") announced today that, further to its previously announced offering of equity securities, it has closed the second tranche of its brokered equity offering, raising an additional US$4 million from a fund managed by Omega Fund Management, LLC ("Omega") as well as the partial exercise by the Canadian agent of its over-allotment option for additional proceeds of approximately US$1 million (collectively, the "Offering"). Together with the initial closing on January 9, 2018 of th
Jan 16, 2018 07:39 am ET
ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 09, 2018 07:43 am ET
ESSA Completes US$21 Million Equity Offering
HOUSTON and VANCOUVER, Jan. 9, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company") announced today that, further to its previously announced offering of equity securities, it has closed an initial US$20,325,000 brokered equity offering (the "Offering") and a concurrent US$675,000 non-brokered private placement (the "Private Placement") for aggregate gross proceeds of US$21 million.
Jan 09, 2018 07:40 am ET
ESSA Completes US$21 Million Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 05, 2018 05:30 pm ET
ESSA announces filing of second amended and restated prospectus supplement and an update to previously announced equity offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 05, 2018 05:30 pm ET
ESSA Announces Filing of Second Amended and Restated Prospectus Supplement and an Update to Previously Announced Equity Offering
HOUSTON and VANCOUVER, Jan. 5, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company") announces a further update to its previously announced equity offering. As previously announced, the Company intends to issue up to 125,000,000 common shares of the Company ("Common Shares") at a price of US$0.20 per Common Share (the "Offering Price") for aggregate gross proceeds of up to US$25 million (the "Offering"). In lieu of a Common Share, purchasers may elect to purchase one pre-funded common share purchase warrant of the Company (a "Warrant") at the Offering Pric
Jan 02, 2018 06:45 pm ET
ESSA Announces Filing of Amended and Restated Prospectus Supplement and an Update to Previously Announced Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 02, 2018 06:45 pm ET
ESSA Announces Filing of Amended and Restated Prospectus Supplement and an Update to Previously Announced Equity Offering
HOUSTON, TX and VANCOUVER, Jan. 2, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company") announces a further update to its previously announced equity offering. The Company intends to issue up to 125,000,000 common shares of the Company ("Common Shares") at a price of US$0.20 per Common Share (the "Offering Price") for aggregate gross proceeds of up to US$25 million (the "Offering"). In lieu of a Common Share, purchasers may elect to receive one pre-funded common share purchase warrant of the Company (a "Warrant"). Each Warrant will entitle the holder ther
Dec 15, 2017 09:52 pm ET
ESSA Announces Filing of Prospectus Supplement and an Update to Previously Announced Equity Offering
HOUSTON, TX and VANCOUVER, Dec. 15, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company") announces an update to its previously announced pricing press release. The Company intends to issue up to 75,000,000 units of the Company ("Units") at a price of US$0.20 per Unit (the "Offering Price") for aggregate gross proceeds of up to US$15 million (the "Offering"). Each Unit will be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"). Each Warrant will be exercisable at a price of US$0.22 and entit
Dec 15, 2017 09:42 pm ET
ESSA Announces Filing of Prospectus Supplement and an Update to Previously Announced Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Dec 13, 2017 09:05 am ET
CORRECTION FROM SOURCE: IIROC Trade Resumption - ESSA Pharma Inc.
Toronto, Ontario--(Newsfile Corp. - December 13, 2017) - Trading resumes in:
Dec 13, 2017 09:02 am ET
IIROC Trade Resumption - ESSA Pharma Inc.
Toronto, Ontario--(Newsfile Corp. - December 13, 2017) - Trading resumes in:
Dec 13, 2017 08:52 am ET
IIROC Trade Halt - ESSA Pharma Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2017) - The following issues have been halted by IIROC:
Dec 13, 2017 08:04 am ET
IIROC Trading Resumption - EPI
VANCOUVER, Dec. 13, 2017 /CNW/ - Trading resumes in:
Dec 13, 2017 07:55 am ET
ESSA Pharma Announces Pricing of Previously Announced Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Dec 13, 2017 07:55 am ET
ESSA Pharma Announces Pricing of Previously Announced Equity Offering
HOUSTON and VANCOUVER, Dec. 13, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, is pleased to announce today that the Company has priced its previously announced offering of equity securities (the "Offering"). Pursuant to the Offering, ESSA intends to issue common shares in the capital of the Company (the "Common Shares") at a price of US$0.20 per Common Share (the "Common Share Price").
Dec 13, 2017 07:55 am ET
IIROC Trading Halt - EPI
VANCOUVER, Dec. 13, 2017 /CNW/ - The following issues have been halted by IIROC:
Dec 12, 2017 04:35 pm ET
ESSA Pharma Announces Overnight Marketed Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Dec 12, 2017 04:22 pm ET
ESSA Pharma Announces Overnight Marketed Equity Offering
HOUSTON and VANCOUVER, Dec. 12, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pre-clinical stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, is pleased to announce that today it has undertaken an overnight marketed public offering (the "Offering") of equity securities of the Company (the "Securities").
Dec 11, 2017 08:21 pm ET
ESSA Pharma Announces Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2017
HOUSTON and VANCOUVER, Dec. 11, 2017 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the fourth quarter and year ended September 30, 2017 and progress on its preclinical development program.
Dec 11, 2017 08:21 pm ET
ESSA Pharma Announces Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2017
HOUSTON and VANCOUVER, Dec. 11, 2017 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the fourth quarter and year ended September 30, 2017 and progress on its preclinical development program.
Nov 22, 2017 04:05 pm ET
ESSA Pharma Announces New Listing on the TSX Venture Exchange Concurrent with Voluntary Delisting from the TSX
TSX VENTURE LISTING EXPECTED TO IMPROVE OPERATING EFFICIENCY, LOWER COSTS AND PROVIDE ENHANCED FINANCING FLEXIBILITY
Nov 22, 2017 04:05 pm ET
ESSA Pharma Announces New Listing on the TSX Venture Exchange Concurrent with Voluntary Delisting from the TSX
TSX VENTURE LISTING EXPECTED TO IMPROVE OPERATING EFFICIENCY, LOWER COSTS AND PROVIDE ENHANCED FINANCING FLEXIBILITY
Sep 11, 2017 08:30 am ET
ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates Clinical and Strategic Plans
Updated data from ongoing Phase 1 trial presented at ESMO
Confirmed EPI-506 is well-tolerated with a favorable safety profile
Long-term stable disease and PSA reductions at higher dose levels in some patients indicate signs of efficacy and suggest the need for a more potent agent
Clinical activity supports inhibition of N-terminal domain of androgen receptor
Company makes strategic decision to prioritize next-generation Aniten program for mCRPC over further clinical development of EPI-506
ESSA initiates corporate restructuring to refocus R&D efforts
Company to present today at Rodman
Sep 11, 2017 08:30 am ET
ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates Clinical and Strategic Plans
Updated data from ongoing Phase 1 trial presented at ESMO
Confirmed EPI-506 is well-tolerated with a favorable safety profile
Long-term stable disease and PSA reductions at higher dose levels in some patients indicate signs of efficacy and suggest the need for a more potent agent
Clinical activity supports inhibition of N-terminal domain of androgen receptor
Company makes strategic decision to prioritize next-generation Aniten program for mCRPC over further clinical development of EPI-506
ESSA initiates corporate restructuring to refocus R&D efforts
Company to present today at Rodman
Sep 07, 2017 08:30 am ET
ESSA Pharma Announces Abstract Presentation on EPI-506 at the European Society for Medical Oncology 2017 Congress
HOUSTON and VANCOUVER, Sept. 7, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced an abstract entitled "EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy" has been selected for a poster presentation at the upcoming 2017 European So
Sep 07, 2017 08:30 am ET
ESSA Pharma Announces Abstract Presentation on EPI-506 at the European Society for Medical Oncology 2017 Congress
HOUSTON and VANCOUVER, Sept. 7, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced an abstract entitled "EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy" has been selected for a poster presentation at the upcoming 2017 Euro
Sep 01, 2017 08:30 am ET
ESSA Pharma to Present at Rodman & Renshaw 19th Annual Global Investment Conference
HOUSTON and VANCOUVER, Sept. 1, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11th, at 4:15 PM Eastern Standard Time at the Lotte New York Palace Hotel.
Sep 01, 2017 08:30 am ET
ESSA Pharma to Present at Rodman & Renshaw 19th Annual Global Investment Conference
HOUSTON and VANCOUVER, Sept. 1, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11th, at 4:15 PM Eastern Standard Time at the Lotte New York Palace Hotel.
Aug 14, 2017 09:55 pm ET
ESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017
HOUSTON, TX and VANCOUVER, Aug. 14, 2017 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the fiscal third quarter ended June 30, 2017 and progress on its clinical development program.
Aug 14, 2017 09:55 pm ET
ESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017
HOUSTON, TX and VANCOUVER, Aug. 14, 2017 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the fiscal third quarter ended June 30, 2017 and progress on its clinical development program.
Jul 24, 2017 08:30 am ET
ESSA Pharma Provides Further Update on Proposed Equity Offering
/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jul 24, 2017 08:30 am ET
ESSA Pharma Provides Further Update on Proposed Equity Offering
HOUSTON and VANCOUVER, July 24, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today provided a further update on its intention to pursue an equity offering. As outlined in its announcement on July 18, 2017, the Company had received sufficient investor interest to advance the proposed transaction but was denied conditional approval by financial regulators due to levels of insider and institutional participation. While
Jul 21, 2017 08:30 am ET
ESSA Pharma Announces Receipt of NASDAQ Notice of Market Value Deficiency
HOUSTON and VANCOUVER, July 21, 2017 /CNW/ - ESSA Pharma Inc. (TSX:EPI; NASDAQ:EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today that it has received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value of listed securities requirement set forth in Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2
Jul 20, 2017 08:30 am ET
ESSA Pharma Announces Receipt of NASDAQ Notice of Bid Price Deficiency
HOUSTON and VANCOUVER, July 20, 2017 /CNW/ - ESSA Pharma Inc. (TSX:EPI; NASDAQ:EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today that it has received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securi
Jul 18, 2017 09:07 am ET
ESSA Pharma Announces Update to Proposed Equity Offering
HOUSTON and VANCOUVER, July 18, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today provided an update on the previously announced offering by way of a prospectus supplement to ESSA's base shelf prospectus dated December 22, 2015 and elsewhere on a private placement basis. Sufficient expressions of interest were received from investors to meet the proposed minimum offering threshold. The company was informed by finan
Jul 18, 2017 09:03 am ET
ESSA Pharma Announces Update to Proposed Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jul 13, 2017 01:11 pm ET
IIROC Trade Resumption - EPI
TORONTO, July 13, 2017 /CNW/ - Trading resumes in:
Jul 13, 2017 12:57 pm ET
ESSA Pharma Announces Pricing Of Proposed Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jul 13, 2017 12:57 pm ET
ESSA Pharma Announces Pricing of Proposed Equity Offering
HOUSTON and VANCOUVER, July 13, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, is pleased to announce today that the Company has priced its previously announced offering of equity securities (the "Proposed Offering"). Pursuant to the Proposed Offering, ESSA intends to issue units of the Company ("Units") at a price of US$0.44 per Unit. Each Unit will be comprised of one common share of the Company (a "Common Share")
Jul 12, 2017 05:18 pm ET
IIROC Trading Halt - EPI
TORONTO, July 12, 2017 /CNW/ - The following issues have been halted by IIROC:
Jul 12, 2017 05:10 pm ET
ESSA Pharma Announces Overnight Marketed Equity Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jul 12, 2017 05:10 pm ET
ESSA Pharma Announces Overnight Marketed Equity Offering
HOUSTON and VANCOUVER, July 12, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today that it has undertaken an overnight marketed public offering (the "Offering") of securities (the "Securities") of the Company. The Offering will be conducted in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to ESSA's base shelf prospectus dated December 22, 2015 and elsewher
Jun 05, 2017 03:30 pm ET
ESSA Pharma Presents Data From Phase 1 Trial of EPI-506 at 2017 ASCO Annual Meeting
Well tolerated to date with an acceptable safety profile
Signs of clinical activity at the higher dose range
Enrollment continues in additional cohorts at higher dose levels
HOUSTON and VANCOUVER, June 5, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced that early data from the Phase 1 portion of the ongoing Phase 1/2 clinical trial of its product candidate, EPI-506, were featured in a poster presentation during
Jun 05, 2017 03:30 pm ET
ESSA Pharma Presents Data From Phase 1 Trial of EPI-506 at 2017 ASCO Annual Meeting
Well tolerated to date with an acceptable safety profile
Signs of clinical activity at the higher dose range
Enrollment continues in additional cohorts at higher dose levels
HOUSTON and VANCOUVER, June 5, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced that early data from the Phase 1 portion of the ongoing Phase 1/2 clinical trial of its product candidate, EPI-506, were featured in a poster presentation
May 17, 2017 06:12 pm ET
ESSA Pharma Announces Data from Phase 1 Trial of EPI-506 to be Presented During 2017 ASCO Annual Meeting
HOUSTON and VANCOUVER, May 17, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced that early data from the Phase 1 portion of the ongoing Phase 1/2 clinical trial of its product candidate, EPI-506, will be presented in a poster presentation at the upcoming 2017 American Society for Clinical Oncology ("ASCO") Annual Meeting held June 2-6, 2017 in Chicago, Illinois. Information contained in the abstract (http://iplanner.
May 17, 2017 06:12 pm ET
ESSA Pharma Announces Data from Phase 1 Trial of EPI-506 to be Presented During 2017 ASCO Annual Meeting
HOUSTON and VANCOUVER, May 17, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced that early data from the Phase 1 portion of the ongoing Phase 1/2 clinical trial of its product candidate, EPI-506, will be presented in a poster presentation at the upcoming 2017 American Society for Clinical Oncology ("ASCO") Annual Meeting held June 2-6, 2017 in Chicago, Illinois. Information contained in the abstract (http://ip
May 15, 2017 08:30 am ET
ESSA Pharma Provides Business Update and Announces Financial Results for the Second Quarter Ended March 31, 2017
HOUSTON and VANCOUVER, May 15, 2017 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the second quarter ended March 31, 2017 and progress on its clinical development program.
May 15, 2017 08:30 am ET
ESSA Pharma Provides Business Update and Announces Financial Results for the Second Quarter Ended March 31, 2017
HOUSTON and VANCOUVER, May 15, 2017 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the second quarter ended March 31, 2017 and progress on its clinical development program.
Apr 12, 2017 09:30 am ET
ESSA to Present at Bloom Burton & Co Healthcare Investor Conference 2017
HOUSTON, TX and VANCOUVER, April 12, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer will be presenting at the Bloom Burton & Co. Healthcare Investor Conference 2017 on Monday May 1st at 9:30am Eastern at the Sheraton Centre Toronto Hotel in Toronto, Canada.
Apr 12, 2017 09:30 am ET
ESSA to Present at Bloom Burton & Co Healthcare Investor Conference 2017
HOUSTON, TX and VANCOUVER, April 12, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer will be presenting at the Bloom Burton & Co. Healthcare Investor Conference 2017 on Monday May 1st at 9:30am Eastern at the Sheraton Centre Toronto Hotel in Toronto, Canada.
Apr 05, 2017 09:30 am ET
ESSA Pharma Receives US$1.2 Million Grant Payment from Cancer Prevention Research Institute of Texas
HOUSTON, TX, April 5, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the receipt of a US$1.2 million payment from the Cancer Prevention Research Institute of Texas ("CPRIT"). The payment is part of a total non-dilutive grant of US$12.0 million originally awarded in July 2014, and is repayable out of potential future product revenues.
Apr 05, 2017 09:30 am ET
ESSA Pharma Receives US$1.2 Million Grant Payment from Cancer Prevention Research Institute of Texas
HOUSTON, TX, April 5, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the receipt of a US$1.2 million payment from the Cancer Prevention Research Institute of Texas ("CPRIT"). The payment is part of a total non-dilutive grant of US$12.0 million originally awarded in July 2014, and is repayable out of potential future product revenues.
Apr 03, 2017 09:30 am ET
ESSA Pharma Provides Clinical Study Update and Announces Presentations at the American Association for Cancer Research Annual Meeting
HOUSTON, TEXAS AND VANCOUVER, CANADA, April 3, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, provided an update today on the status of its Phase 1 clinical study of EPI-506 for patients with metastatic castration-resistant prostate cancer ("mCRPC"). EPI-506 targets the N-terminal domain ("NTD") of the androgen receptor (AR) – a novel approach to AR inhibition. Research into NTD AR biology is also being highlighted in three posters at the
Apr 03, 2017 09:30 am ET
ESSA Pharma Provides Clinical Study Update and Announces Presentations at the American Association for Cancer Research Annual Meeting
HOUSTON, TEXAS AND VANCOUVER, CANADA, April 3, 2017 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, provided an update today on the status of its Phase 1 clinical study of EPI-506 for patients with metastatic castration-resistant prostate cancer ("mCRPC"). EPI-506 targets the N-terminal domain ("NTD") of the androgen receptor (AR) – a novel approach to AR inhibition. Research into NTD AR biology is also being highlighted in three posters
Mar 14, 2017 05:30 pm ET
ESSA to Present at 29th Annual Roth Conference and Rodman & Renshaw Premier Series - A Future Without Cancer
HOUSTON and VANCOUVER, March 14, 2017 /CNW/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that David R. Parkinson, President and Chief Executive Officer will be presenting at the 29TH Annual Roth Conference on Wednesday March 15th at 11:30am in Laguna Beach, CA and at Rodman & Renshaw Premier Series – A Future Without Cancer on Friday March 17th at 2:00pm in Palm Beach, FL.
Mar 08, 2017 07:16 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON, TX and VANCOUVER, March 8, 2017 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on March 8, 2017 in Vancouver, BC (the "Meeting").
Mar 08, 2017 07:16 pm ET
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON, TX and VANCOUVER, March 8, 2017 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on March 8, 2017 in Vancouver, BC (the "Meeting").
Feb 13, 2017 08:30 am ET
ESSA Pharma Provides Business Update and Announces Financial Results for the First Quarter Ended December 31, 2016
HOUSTON, TX, and VANCOUVER, Feb. 13, 2017 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the first quarter ended December 31, 2016 and progress on its clinical development program.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.